Back to Crohns Disease And Colitis
NCT02641392
NCT02641392
Who may be able to join
Who might be able to join this trial:
- You are 18 years of age or older (for adult participants)
- You previously took part in a specific related clinical study called GED-0301-CD-002 or GED-0301-CD-003
- You are willing and able to use an approved method of contraception as required by the study
- You are between 12 and 17 years old (for adolescent participants)
- As an adolescent, you previously took part in the specific related clinical study called GED-0301-CD-003
- As an adolescent, you are able to swallow tablets
- As an adolescent, you are willing and able to use an approved method of contraception as required by the study
Who may not be able to join:
- You had a serious side effect related to the study medication during your participation in the previous related clinical study
- You have recently started taking certain biological medicines, such as TNF-alpha blockers or integrin antagonists (confirm with trial site)
- You are currently pregnant or breastfeeding
- You have developed a known allergy or sensitivity to the study drug or any of its ingredients
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Terminated
Phase
Phase 3
Sponsor
Celgene
Registry
clinicaltrials_gov
Start date
25 July 2016
Est. completion
4 January 2018
Where this trial is recruiting
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇬 Bulgaria
🇨🇦 Canada
🇭🇷 Croatia
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇭🇺 Hungary
🇮🇱 Israel
🇮🇹 Italy
🇱🇻 Latvia
🇳🇱 Netherlands
🇳🇴 Norway
🇵🇱 Poland
🇵🇹 Portugal
🇷🇴 Romania
🇷🇺 Russia
🇷🇸 Serbia
🇸🇰 Slovakia
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇨🇭 Switzerland
Turkey (Türkiye)
🇺🇦 Ukraine
🇬🇧 United Kingdom
🇺🇸 United States
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants With Treatment Emergent Adverse Events From Week 0 to Week 208
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.